10x Genomics Debuts Range of New Products at AGBT
February 24 2020 - 12:00PM
10x Genomics, Inc. (Nasdaq: TXG) today announced a broad range of
new products at the Advances in Genome Biology and Technology
(AGBT) General Meeting, as well as new capabilities for existing
products. Today’s announcements further 10x Genomics’ commitment to
helping researchers see biology at greater resolution and scale,
conduct more simultaneous measurements, and have richer context for
their work regardless of the size or location of their labs.
The company also announced that its new Chromium Connect system
is now shipping. Chromium Connect automates single cell workflows,
maximizing lab productivity while reducing user variability to
generate consistent, reproducible single cell sequencing results.
10x Genomics unveiled the development of four new Targeted Gene
Expression products for Pan-Cancer, Immunology, Gene Signature, and
Neuroscience that will work across the company’s Chromium and
Visium platforms. Targeted Gene Expression products are expected to
ship in mid-2020.
“The new products and features we have in the pipeline will
empower scientists to study biology at greater resolution and scale
than ever before,” said Michael Schnall-Levin, senior vice
president of research and development and founding scientist at 10x
Genomics. “Last year at AGBT we previewed our Visium Spatial Gene
Expression Solution, which has now shipped to customers around the
world. With today’s announcement of over a dozen product offerings,
we are on a rapid rate of innovation to make the Century of Biology
a reality.”
Continuing its role as a pioneer in single cell genomics, the
company also revealed the following new applications for its
Chromium platform:
- Chromium Single Cell ATAC + Gene Expression -
For the first time, 10x Genomics customers will be able to measure
simultaneous epigenetic and gene expression markers from the same
single cell at scale. The product is expected to arrive in the
second half of the year.
- CellPlex - The new offering will provide
flexibility for customers to run experiments on a scale of up to
160K cells or multiplex up to 96 samples per run on an 8-channel
chip. In combination with other 10x Genomics innovations, this
offering will allow for routine million-cell experiments. CellPlex
is expected to be available in the second half of the
year.
Additionally, together with its partners the company has
demonstrated the ability to measure intracellular proteins together
with gene expression in single cells using its Feature Barcode
technology.
For the Visium Spatial Gene Expression Solution that began
shipping in November 2019, allowing researchers to map where gene
activity is occurring in a tissue, 10x Genomics is offering new
products and capabilities:
- IHC Compatibility - Customers will be able to
measure proteins and gene expression in tissue from the same sample
at the same time, significantly increasing the overall amount of
information gleaned. It is expected to be available in the first
half of the year.
- Visium Spatial Gene Expression with Feature Barcode
Technology - The new product will allow tens to hundreds
of proteins to be measured together with gene expression on the
same sample and is planned for availability in the first half of
2021.
- FFPE (Formalin-Fixed Paraffin
Embedded) Compatibility - This new
extension will enable Visium to work with FFPE tissues, the most
common sample type for translational and clinical researchers. A
number of customers are testing this capability in an early
version. The company is targeting to release a separate dedicated
FFPE solution in the first half of 2021.
Later this year the company will release its new 10x Cloud
Analysis, a fast, efficient, safe and secure SaaS analysis for its
most popular applications: Cell Ranger, Space Ranger, and Loupe
visualization. Cloud Analysis will enable users to integrate their
existing systems and workflows and scale up to large experiments
without the need for investing in expensive hardware.
To learn more, visit 10xgenomics.com/future.
About 10x Genomics10x Genomics is a life
science technology company building products to interrogate,
understand and master biology to advance human health. The
company’s integrated solutions include instruments, consumables and
software for analyzing biological systems at a resolution and scale
that matches the complexity of biology. 10x Genomics products have
been adopted by researchers around the world including 97 of the
top 100 global research institutions and 19 of the top 20 global
pharmaceutical companies, and have been cited in over 700 research
papers on discoveries ranging from oncology to immunology and
neuroscience. The company's patent portfolio comprises more than
700 issued patents and patent applications.
Forward Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 as contained in
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements generally can be identified by the use
of forward-looking terminology such as “may,” “will,” “should,”
“expect,” “plan,” “anticipate,” “could,” “intend,” “target,”
“project” “contemplate,” “believe,” “estimate,” “predict,”
“potential” or “continue” or the negatives of these terms or
variations of them or similar terminology. These
forward-looking statements include statements regarding potential
new features and products, which involve risks and uncertainties
that could cause outcomes to differ materially from the
expectations expressed in these forward-looking statements. These
statements are based on management’s current expectations,
forecasts, beliefs, assumptions and information currently available
to management, and actual outcomes could differ materially from
these statements due to a number of factors. These and additional
risks and uncertainties that could affect 10x Genomics, Inc.’s
financial and operating results and cause actual results to differ
materially from those indicated by the forward-looking statements
made in this press release include those discussed under the
captions "Risk Factors" and "Management's Discussion and Analysis
of Financial Condition and Results of Operations" and elsewhere in
the documents 10x Genomics, Inc. files with the Securities and
Exchange Commission from time to time. The forward-looking
statements in this press release are based on information available
to 10x Genomics, Inc. as of the date hereof, and 10x Genomics, Inc.
disclaims any obligation to update any forward-looking statements
provided to reflect any change in its expectations or any change in
events, conditions, or circumstances on which any such statement is
based, except as required by law. These forward-looking statements
should not be relied upon as representing 10x Genomics, Inc.’s
views as of any date subsequent to the date of this press
release.
Disclosure Information10x Genomics uses filings
with the Securities and Exchange Commission, its website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and its social media accounts as means of
disclosing material non-public information and for complying with
its disclosure obligations under Regulation FD.
ContactsInvestors:investors@10xgenomics.com Media:media@10xgenomics.com
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Jul 2023 to Jul 2024